The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Clinical trial NCT01961921 · COMPLETED
Trial details
- NCT number
- NCT01961921
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-10-01
- Primary completion
- 2016-07-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.